238 related articles for article (PubMed ID: 18760319)
1. A heterologous DNA prime/protein boost immunization strategy for rhesus cytomegalovirus.
Abel K; Strelow L; Yue Y; Eberhardt MK; Schmidt KA; Barry PA
Vaccine; 2008 Nov; 26(47):6013-25. PubMed ID: 18760319
[TBL] [Abstract][Full Text] [Related]
2. Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques.
Abel K; Martinez J; Yue Y; Lacey SF; Wang Z; Strelow L; Dasgupta A; Li Z; Schmidt KA; Oxford KL; Assaf B; Longmate JA; Diamond DJ; Barry PA
J Virol; 2011 Mar; 85(6):2878-90. PubMed ID: 21191005
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and protective efficacy of DNA vaccines expressing rhesus cytomegalovirus glycoprotein B, phosphoprotein 65-2, and viral interleukin-10 in rhesus macaques.
Yue Y; Kaur A; Eberhardt MK; Kassis N; Zhou SS; Tarantal AF; Barry PA
J Virol; 2007 Feb; 81(3):1095-109. PubMed ID: 17108040
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity evaluation of DNA vaccines that target guinea pig cytomegalovirus proteins glycoprotein B and UL83.
Schleiss MR; Bourne N; Jensen NJ; Bravo F; Bernstein DI
Viral Immunol; 2000; 13(2):155-67. PubMed ID: 10892996
[TBL] [Abstract][Full Text] [Related]
5. Development of a vaccine against murine cytomegalovirus (MCMV), consisting of plasmid DNA and formalin-inactivated MCMV, that provides long-term, complete protection against viral replication.
Morello CS; Ye M; Spector DH
J Virol; 2002 May; 76(10):4822-35. PubMed ID: 11967299
[TBL] [Abstract][Full Text] [Related]
6. The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB.
Lilja AE; Mason PW
Vaccine; 2012 Nov; 30(49):6980-90. PubMed ID: 23041121
[TBL] [Abstract][Full Text] [Related]
7. Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.
Chiuppesi F; Nguyen J; Park S; Contreras H; Kha M; Meng Z; Kaltcheva T; Iniguez A; Martinez J; La Rosa C; Wussow F; Diamond DJ
J Virol; 2018 Oct; 92(19):. PubMed ID: 30045984
[TBL] [Abstract][Full Text] [Related]
8. Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.
Schleiss MR; Berka U; Watson E; Aistleithner M; Kiefmann B; Mangeat B; Swanson EC; Gillis PA; Hernandez-Alvarado N; Fernández-Alarcón C; Zabeli JC; Pinschewer DD; Lilja AE; Schwendinger M; Guirakhoo F; Monath TP; Orlinger KK
Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27795301
[TBL] [Abstract][Full Text] [Related]
9. Characterization and immunological analysis of the rhesus cytomegalovirus homologue (Rh112) of the human cytomegalovirus UL83 lower matrix phosphoprotein (pp65).
Yue Y; Kaur A; Zhou SS; Barry PA
J Gen Virol; 2006 Apr; 87(Pt 4):777-787. PubMed ID: 16528025
[TBL] [Abstract][Full Text] [Related]
10. Dominant Antiviral CD8
Pardieck IN; van Duikeren S; Veerkamp DMB; Brasem DJ; Redeker A; van Bergen J; Han W; Ossendorp F; Zondag G; Arens R
Front Immunol; 2022; 13():680559. PubMed ID: 35154089
[TBL] [Abstract][Full Text] [Related]
11. Strong CD8 T-cell responses following coimmunization with plasmids expressing the dominant pp89 and subdominant M84 antigens of murine cytomegalovirus correlate with long-term protection against subsequent viral challenge.
Ye M; Morello CS; Spector DH
J Virol; 2002 Mar; 76(5):2100-12. PubMed ID: 11836387
[TBL] [Abstract][Full Text] [Related]
12. Comparison of vaccination with rhesus CMV (RhCMV) soluble gB with a RhCMV replication-defective virus deleted for MHC class I immune evasion genes in a RhCMV challenge model.
Valencia S; Gill RB; Dowdell KC; Wang Y; Hornung R; Bowman JJ; Lacayo JC; Cohen JI
Vaccine; 2019 Jan; 37(2):333-342. PubMed ID: 30522906
[TBL] [Abstract][Full Text] [Related]
13. Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection.
Wang Z; La Rosa C; Lacey SF; Maas R; Mekhoubad S; Britt WJ; Diamond DJ
J Clin Virol; 2006 Mar; 35(3):324-31. PubMed ID: 16388983
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of recombinant modified vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques.
Yue Y; Wang Z; Abel K; Li J; Strelow L; Mandarino A; Eberhardt MK; Schmidt KA; Diamond DJ; Barry PA
Med Microbiol Immunol; 2008 Jun; 197(2):117-23. PubMed ID: 18196272
[TBL] [Abstract][Full Text] [Related]
15. DNA vaccine prime followed by boost with live attenuated virus significantly improves antigen-specific T cell responses against human cytomegalovirus.
Gil A; Shen S; Coley S; Gibson L; Diamond DJ; Wang S; Lu S
Hum Vaccin Immunother; 2013 Oct; 9(10):2120-32. PubMed ID: 24051429
[TBL] [Abstract][Full Text] [Related]
16. Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection against pup mortality.
Swanson EC; Gillis P; Hernandez-Alvarado N; Fernández-Alarcón C; Schmit M; Zabeli JC; Wussow F; Diamond DJ; Schleiss MR
Vaccine; 2015 Jul; 33(32):4013-8. PubMed ID: 26079615
[TBL] [Abstract][Full Text] [Related]
17. Optimization of DNA immunization against human cytomegalovirus.
Endrész V; Burián K; Berencsi K; Gyulai Z; Kari L; Horton H; Virok D; Méric C; Plotkin SA; Gönczöl E
Vaccine; 2001 Jul; 19(28-29):3972-80. PubMed ID: 11427273
[TBL] [Abstract][Full Text] [Related]
18. Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques.
Iyer SS; Gangadhara S; Victor B; Shen X; Chen X; Nabi R; Kasturi SP; Sabula MJ; Labranche CC; Reddy PB; Tomaras GD; Montefiori DC; Moss B; Spearman P; Pulendran B; Kozlowski PA; Amara RR
J Virol; 2016 Oct; 90(19):8842-54. PubMed ID: 27466414
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo stimulation and expansion of both CD4(+) and CD8(+) T cells from peripheral blood mononuclear cells of human cytomegalovirus-seropositive blood donors by using a soluble recombinant chimeric protein, IE1-pp65.
Vaz-Santiago J; Lulé J; Rohrlich P; Jacquier C; Gibert N; Le Roy E; Betbeder D; Davignon JL; Davrinche C
J Virol; 2001 Sep; 75(17):7840-7. PubMed ID: 11483727
[TBL] [Abstract][Full Text] [Related]
20. Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization.
Endresz V; Kari L; Berencsi K; Kari C; Gyulai Z; Jeney C; Pincus S; Rodeck U; Méric C; Plotkin SA; Gönczöl E
Vaccine; 1999 Jan; 17(1):50-8. PubMed ID: 10078607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]